Patents Assigned to Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc.
  • Methods of diagnosing or treating prostate cancer using the ERG gene, alone or in combination with other over or under expressed genes in prostate cancer
    Patent number: 9868993
    Abstract: The present invention relates to oncogenes or tumor suppressor genes, as well as other genes, involved in prostate cancer and their expression products, as well as derivatives and analogs thereof. Provided are therapeutic compositions and methods of detecting and treating cancer, including prostate and other related cancers. Also provided are methods of diagnosing and/or prognosing prostate cancer by determining the expression level of at least one prostate cancer-cell-specific gene, including, for example, the ERG gene or the LTF gene alone, or in combination with at least one of the AMACR gene and the DD3 gene.
    Type: Grant
    Filed: May 18, 2016
    Date of Patent: January 16, 2018
    Assignee: The Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc.
    Inventors: Gyorgy Petrovics, Shiv Srivastava
  • System and stent for repairing endovascular defects and methods of use
    Patent number: 9839724
    Abstract: Disclosed are endovascular stents in which a portion of the stents have a bioactive coating for promoting repair of damaged vessels, systems comprising the stents, and methods of using the stents to promote occlusion of aneurysms and/or repair damaged vessels.
    Type: Grant
    Filed: March 20, 2017
    Date of Patent: December 12, 2017
    Assignees: Purdue Research Foundation, The Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc.
    Inventors: Jean Paul Allain, Lisa Reece, Zhangcan Yang, Rocco Armonda, Ravindra Kempaiah, Teodoro Tigno
  • Methods and compositions based on Shiga toxin type 2 protein
    Patent number: 9801931
    Abstract: The invention is based on the discovery of the epitope in the Stx2 protein for the 11 E1O antibody. The invention features compositions containing non-full length Stx2 polypeptides that include the 11 E1O monoclonal antibody epitope. The invention also features methods of producing anti-Stx2 antibodies specific for the 11 E1O epitope of the Stx2 protein. Additionally, the invention features methods for treating a subject having, or at risk of developing, a Shiga toxin associated disease (e.g., hemolytic uremia syndrome and diseases associated with E. coli and S. dysenteriae infection) with a polypeptide that includes the 11 E1O epitope or with an anti-Stx2 antibody developed using the methods of the invention. Furthermore, the invention features the detection of Stx2 in a sample using the antibodies developed using the methods of the invention.
    Type: Grant
    Filed: February 23, 2015
    Date of Patent: October 31, 2017
    Assignee: The Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc.
    Inventors: Alison D. O'Brien, Angela Melton-Celsa, Michael Smith, James Sinclair
  • Inhibitors for ERG oncogene positive cancers
    Patent number: 9782394
    Abstract: Alterations to the ERG gene are some of the most prominent genomic changes associated with many cancers including prostate cancer. Such cancer specific alterations result in the overexpression of wild type ERG protein or an altered ERG protein. The present invention provides selective inhibitors of wild type or an altered ERG protein expression. The ERG inhibitors of the invention, therefore, are therapeutic agents for treating ERG positive cancers.
    Type: Grant
    Filed: March 12, 2015
    Date of Patent: October 10, 2017
    Assignee: The Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc.
    Inventors: Clifton Dalgard, Ahmed Mohamed, Meera Srivastava, Shiv Srivastava
  • Compositions containing amino acids, phosphate and manganese and their uses
    Patent number: 9758760
    Abstract: The invention provides methods of producing vaccines directed against microorganisms, with the methods comprising culturing, harvesting and/or suspending the microorganism in the presence of a radiation-protective composition and irradiating the bacteria or viruses with a dose of radiation sufficient to render the microorganism replication-deficient and/or non-infective. The radiation-protective compositions used in the methods of the present invention comprise at least one nucleoside, at least one antioxidant and at least one small peptide. The invention also provides methods of rendering bacteria in culture resistant to ionizing radiation (IR), with these methods comprising culturing the bacteria in the presence of a radiation-protective composition.
    Type: Grant
    Filed: December 8, 2015
    Date of Patent: September 12, 2017
    Assignee: The Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc.
    Inventors: Michael J. Daly, Elena K. Gaidamakova
  • Vaccine for the prevention of breast cancer recurrence
    Patent number: 9737596
    Abstract: Provided are methods to induce and maintain a protective cytotoxic T-lymphocyte response to a peptide of the HER2/neu oncogene, GP2, with the effect of inducing and maintaining protective or therapeutic immunity against breast cancer in a patient in clinical remission, including patients having low to intermediate levels of HER2/neu expression. The methods comprise administering to the patient an effective amount of a vaccine composition comprising a pharmaceutically acceptable carrier, an adjuvant such as GM-CSF, and the GP2 peptide. The methods may further comprise administering a periodic booster vaccine dose as needed due to declining GP2-specific T cell immunity. Also provided are vaccine compositions for use in the methods.
    Type: Grant
    Filed: July 30, 2015
    Date of Patent: August 22, 2017
    Assignee: The Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc.
    Inventors: George Peoples, Sathibalan Ponniah
  • Targeted identification of immunogenic peptides
    Patent number: 9720000
    Abstract: This invention relates generally to identifying peptide sequences involved in antibody binding to any protein for synthesis of vaccine treatments. This novel method allows for a more manageable vaccine peptide discovery and specific generation of unique immunogenic peptides from self-tumor associated proteins and/or foreign proteins from infectious organisms for specific and/or enhanced expression only in the presence of the antibody.
    Type: Grant
    Filed: May 15, 2015
    Date of Patent: August 1, 2017
    Assignee: The Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc.
    Inventors: Sathibalan Ponniah, George E Peoples, Catherine E Storrer, Michael Flora
  • SYSTEM AND STENT FOR REPAIRING ENDOVASCULAR DEFECTS AND METHODS OF USE
    Publication number: 20170189584
    Abstract: Disclosed are endovascular stents in which a portion of the stents have a bioactive coating for promoting repair of damaged vessels, systems comprising the stents, and methods of using the stents to promote occlusion of aneurysms and/or repair damaged vessels.
    Type: Application
    Filed: March 20, 2017
    Publication date: July 6, 2017
    Applicants: Purdue Research Foundation, The Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc., US Army, Secretary of the Army
    Inventors: Jean Paul Allain, Lisa Reece, Zhangcan Yang, Rocco Armonda, Ravindra Kempaiah, Teodoro Tigno
  • USING B-CELL-TARGETING ANTIGEN IGG FUSION AS TOLEROGENIC PROTEIN THERAPY FOR TREATING ADVERSE IMMUNE RESPONSES
    Publication number: 20170121379
    Abstract: The present invention generally relates to antigen-specific tolerogenic protein therapy and the use thereof for treating adverse immune responses, including those associated with autoimmune diseases such as multiple sclerosis (MS) and hemophilia. In particular, the invention involves the application of a B cell-targeting IgG fusion protein as the antigen-specific tolerogenic protein therapy, either alone or in combination with inhibitory antibodies. The fusion protein comprises a B-cell specific targeting module, the constant region of the human IgG4 heavy chain or a fragment thereof; and an antigen.
    Type: Application
    Filed: May 7, 2015
    Publication date: May 4, 2017
    Applicant: THE HENRY M. JACKSON FOUNDATION FOR THE ADVANCEMENT OF MILITARY MEDICINE, INC.
    Inventors: Ai-Hong ZHANG, David SCOTT
  • Induction of tumor immunity by variants of folate binding protein
    Patent number: 9562070
    Abstract: The present invention is directed to variants of antigens comprising folate binding protein epitopes as a composition associated with providing immunity against a tumor in an individual. The variant is effective in inducing cytotoxic T-lymphocytes but preferably not to the extent that they become sensitive to silencing by elimination, such as by apoptosis, or by anergy, as in unresponsiveness.
    Type: Grant
    Filed: July 24, 2014
    Date of Patent: February 7, 2017
    Assignees: Board of Regents, The University of Texas System, The Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc.
    Inventors: Constantin G. Ioannides, George E. Peoples
  • Soluble forms of hendra and nipah virus G glycoprotein
    Patent number: 9533038
    Abstract: This invention relates to soluble forms of G glycoprotein from Hendra and Nipah virus. In particular, this invention relates to compositions comprising soluble forms of G glycoprotein from Hendra and Nipah virus and also to diagnostic and therapeutic methods using the soluble forms of G glycoprotein from Hendra and Nipah virus. Further, the invention relates to therapeutic antibodies including neutralizing antibodies, and vaccines for the prevention and treatment of infection by Hendra and Nipah viruses.
    Type: Grant
    Filed: April 30, 2015
    Date of Patent: January 3, 2017
    Assignee: The Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc.
    Inventors: Christopher C. Broder, Katharine N. Bossart
  • Methods of diagnosing or treating prostate cancer using the erg gene, alone or in combination with other over or under expressed genes in prostate cancer
    Patent number: 9464325
    Abstract: The present invention relates to oncogenes or tumor suppressor genes, as well as other genes, involved in prostate cancer and their expression products, as well as derivatives and analogs thereof. Provided are therapeutic compositions and methods of detecting and treating cancer, including prostate and other related cancers. Also provided are methods of diagnosing and/or prognosing prostate cancer by determining the expression level of at least one prostate cancer-cell-specific gene, including, for example, the ERG gene or the LTF gene alone, or in combination with at least one of the AMACR gene and the DD3 gene.
    Type: Grant
    Filed: June 27, 2012
    Date of Patent: October 11, 2016
    Assignee: The Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc.
    Inventors: Gyorgy Petrovics, Shiv Srivastava
  • -derived vector and methods of using the same
    Patent number: 9434772
    Abstract: Recombinant vectors comprising the cell entry region of the Shigella ox EIEC invasion plasmid are provided, as well as, Shigella or EIEC strains comprising the recombinant vectors. The vectors provide an improved platform for developing attenuated vaccine strains of Shigella or EiEC and for delivering other foreign proteins of interest. The recombinant vectors and bacterial strains comprising the same may be used in methods of inducing an immune response.
    Type: Grant
    Filed: September 13, 2012
    Date of Patent: September 6, 2016
    Assignee: The Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc.
    Inventor: Anthony T. Maurelli
  • Electrospun dextran fibers and devices formed therefrom
    Patent number: 9399082
    Abstract: The invention generally relates to dextran fibers which are preferably electrospun and devices formed from such fibers. In particular, such devices may include substances of interest (such as therapeutic substances) associated with the electrospun fibers. Upon exposure to a liquid the electrospun fibers dissolve immediately and the substances of interest are released into the liquid. Exemplary devices include bandages formed from electrospun dextran fibers and associated agents that promote hemostasis, such as thrombin and fibrinogen.
    Type: Grant
    Filed: April 10, 2009
    Date of Patent: July 26, 2016
    Assignees: The Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc., Virginia Commonwealth University
    Inventors: Gary L. Bowlin, David G. Simpson, James R. Bowman, Stephen W. Rothwell
  • Portable hand pump for evacuation of fluids
    Patent number: 9393353
    Abstract: A manually operable pump for the effective removal of fluids to include blood, blood clots, fluid, and air from a body cavity of a subject is provided. The manually operable pump is adapted to be connect to a range of fluid conduits and is equipped with one-way valves that effectively permit flow of fluid through the pump in only one direction. The sensitivity of the one-way valves is such that when properly positioned, fluid can flow through the valves and out of the pump without manual compression of the pump and with the aid of gravity power alone.
    Type: Grant
    Filed: January 23, 2014
    Date of Patent: July 19, 2016
    Assignee: The Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc.
    Inventors: Hasan B. Alam, Peter Rhee, Emily Rhee
  • DESIGN AND USE OF SPECIFIC REGULATORY T-CELLS TO INDUCE IMMUNE TOLERANCE
    Publication number: 20160194605
    Abstract: The present invention generally relates to the production of antigen-specific T regulatory cells (Tregs). Such cells can be used in therapy to minimize undesirable immune responses such as those observed in autoimmunity and hemophilia and other diseases as well as in the response to protein therapy for genetic diseases. Methods for producing antigen specific Tregs and conditions for preferential expansion of functionally stable, specific Tregs are also provided.
    Type: Application
    Filed: May 9, 2014
    Publication date: July 7, 2016
    Applicant: THE HENRY M. JACKSON FOUNDATION FOR THE ADVANCEMENT OF MILITARY MEDICINE, INC.
    Inventors: David W. Scott, Yong Chan Kim
  • SKIN SUBSTITUTES AND METHODS FOR HAIR FOLLICLE NEOGENESIS
    Publication number: 20160184481
    Abstract: This invention provides compositions in the form of skin substitutes comprising epithelial cells and mesenchymal cells, wherein the mesenchymal cells are not isolated from the occipital or nape region of the scalp, as well as methods for using the same.
    Type: Application
    Filed: May 1, 2014
    Publication date: June 30, 2016
    Applicant: The Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc.
    Inventors: Rajesh Thangapazham, Thomas N. Darling, Shaowei Li
  • Vaccine for the prevention of breast cancer relapse
    Patent number: 9370560
    Abstract: The invention features methods to induce and maintain a protective cytotoxic T-lymphocyte response to a peptide of the HER2/neu oncogene, E75, with the effect of inducing and maintaining protective or therapeutic immunity against breast cancer in a patient in clinical remission. The methods comprise administering to the patient an effective amount of a vaccine composition comprising a pharmaceutically acceptable carrier, an adjuvant such as recombinant human GM-CSF, and the E75 peptide at an optimized dose and schedule. The methods further comprise administering an annual or semi-annual booster vaccine dose due to declining E75-specific T cell immunity. The invention also features vaccine compositions for use in the methods.
    Type: Grant
    Filed: July 9, 2014
    Date of Patent: June 21, 2016
    Assignee: The Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc.
    Inventors: George E. Peoples, Sathibalan Ponniah
  • Methods of diagnosing or treating prostate cancer using the ERG gene, alone or in combination with other over or under expressed genes in prostate cancer
    Patent number: 9347101
    Abstract: The present invention relates to oncogenes or tumor suppressor genes, as well as other genes, involved in prostate cancer and their expression products, as well as derivatives and analogs thereof. Provided are therapeutic compositions and methods of detecting and treating cancer, including prostate and other related cancers. Also provided are methods of diagnosing and/or prognosing prostate cancer by determining the expression level of at least one prostate cancer-cell-specific gene, including, for example, the ERG gene or the LTF gene alone, or in combination with at least one of the AMACR gene and the DD3 gene.
    Type: Grant
    Filed: January 31, 2013
    Date of Patent: May 24, 2016
    Assignee: The Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc.
    Inventors: Gyorgy Petrovics, Shiv Srivastava
  • Isolation and detection of cancer cells
    Patent number: 9335327
    Abstract: Provided are methods of using polycarbonate filters to isolate and detect cancer cells in a biological fluid, particularly biological fluids, such as urine, that contain very low concentrations of cancer cells. The characterization of the isolated cells for the presence or absence of cancer specific proteins is useful for cancer diagnosis and prognosis.
    Type: Grant
    Filed: August 8, 2012
    Date of Patent: May 10, 2016
    Assignee: The Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc.
    Inventors: Shiv K. Srivastava, Gyorgy Petrovics, Shyh-Han Tan, Kristen Nickens